Gonne, E., Goffinet, L., Geraerts, A., LEBEAU, A., Pleyers, C., Seidel, L., Pauwen, S., Darimont, C., Meuris, F., PIRON, M., Kakkos, A., Schoenen, S., Goffin, F., Delbecque, K., Lovinfosse, P., Danthine, D., Kridelka, F., & Gennigens, C. (February 2025). Survival Of Patients Over 70 Years Old With Locally Advanced Cervical Cancer : A Retrospective Analysis. International Journal of Gynecological Cancer, 35 (2), 100518. doi:10.1016/j.ijgc.2024.100518 |
LEBEAU, A., Goffinet, L., Geraerts, A., Pleyers, C., Gonne, E., Seidel, L., Pauwen, S., Darimont, C., Meuris, F., PIRON, M., Kakkos, A., Schoenen, S., Goffin, F., Delbecque, K., Lovinfosse, P., Danthine, D., Kridelka, F., & Gennigens, C. (2025). Analysis Of Tumour Characteristics Associated With Visceral Recurrence In Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer. doi:10.1016/j.ijgc.2024.100501 |
LAPAILLE, L., Lenom, M., Gonne, E., PIRON, M., Goffin, F., Kakkos, A., Schoenen, S., Kridelka, F., Delbecque, K., PLEYERS, C., Seidel, L., Lovinfosse, P., Danthine, D., LEBEAU, A., & Gennigens, C. (2024). EV285/#587 Neoadjuvant versus adjuvant chemotherapy in high-grade epithelial ovarian cancer: a retrospective study. International Journal of Gynecological Cancer, 231.3-A232. doi:10.1136/ijgc-2024-igcs.404 |
LEBEAU, A., Lenom, M., LAPAILLE, L., Gonne, E., PIRON, M., Goffin, F., Kakkos, A., Schoenen, S., Delbecque, K., PLEYERS, C., Seidel, L., Lovinfosse, P., Danthine, D., Kridelka, F., & Gennigens, C. (2024). EV286/#550 Hormone receptors expression in high-grade epithelial ovarian cancers: a retrospective study. International Journal of Gynecological Cancer, 232.1-A232. doi:10.1136/ijgc-2024-igcs.405 |
Beguin, Y., Dujardin, C., Piron, M., & Vanstraelen, G. (2006). Treatment of anaemia with erythropoietin. In C. Brugnara & C. Beaumont, ESH Scientific Updates. Disorders of Iron Homeostasis, Erythrocytes and erythropoiesis (pp. 180-209). Elsevier Science. |
Piron, M., Loo, M., Gothot, A., Tassin, F., Fillet, G., & Beguin, Y. (2001). Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia. Blood, 97 (2), 442-8. doi:10.1182/blood.V97.2.442 |